161 related articles for article (PubMed ID: 36806862)
1. Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA Data.
Tang F; Hammel IS; Andrew MK; Ruiz JG
J Nutr Health Aging; 2023; 27(2):81-88. PubMed ID: 36806862
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study.
Tang F; Hammel IS; Andrew MK; Ruiz JG
Lancet Healthy Longev; 2022 Sep; 3(9):e589-e598. PubMed ID: 35935474
[TBL] [Abstract][Full Text] [Related]
3. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans.
Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS
JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study.
Bruxvoort KJ; Sy LS; Qian L; Ackerson BK; Luo Y; Lee GS; Tian Y; Florea A; Aragones M; Tubert JE; Takhar HS; Ku JH; Paila YD; Talarico CA; Tseng HF
BMJ; 2021 Dec; 375():e068848. PubMed ID: 34911691
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS).
Maeda H; Saito N; Igarashi A; Ishida M; Suami K; Yagiuchi A; Kimura Y; Komino M; Arai H; Morikawa T; Motohashi I; Miyazawa R; Moriyama T; Kamura H; Terada M; Kuwamitsu O; Hayakawa T; Sando E; Ohara Y; Teshigahara O; Suzuki M; Morimoto K
Clin Infect Dis; 2022 Nov; 75(11):1971-1979. PubMed ID: 35438137
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
Feldstein LR; Britton A; Grant L; Wiegand R; Ruffin J; Babu TM; Briggs Hagen M; Burgess JL; Caban-Martinez AJ; Chu HY; Ellingson KD; Englund JA; Hegmann KT; Jeddy Z; Lauring AS; Lutrick K; Martin ET; Mathenge C; Meece J; Midgley CM; Monto AS; Newes-Adeyi G; Odame-Bamfo L; Olsho LEW; Phillips AL; Rai RP; Saydah S; Smith N; Steinhardt L; Tyner H; Vandermeer M; Vaughan M; Yoon SK; Gaglani M; Naleway AL
JAMA; 2024 Feb; 331(5):408-416. PubMed ID: 38319331
[TBL] [Abstract][Full Text] [Related]
8. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.
Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S
JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110
[TBL] [Abstract][Full Text] [Related]
9. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant.
Eick-Cost AA; Ying S; Wells N
JAMA Netw Open; 2022 Apr; 5(4):e228071. PubMed ID: 35442453
[TBL] [Abstract][Full Text] [Related]
12. Frailty as a risk factor for post-acute sequelae of COVID-19 among US veterans during the Delta and Omicron waves.
Hammel IS; Tosi DM; Tang F; Pott H; Ruiz JG
J Am Geriatr Soc; 2023 Dec; 71(12):3826-3835. PubMed ID: 37725480
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
[TBL] [Abstract][Full Text] [Related]
14. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting.
Butt AA; Omer SB; Yan P; Shaikh OS; Mayr FB
Ann Intern Med; 2021 Oct; 174(10):1404-1408. PubMed ID: 34280332
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans.
Young-Xu Y; Zwain GM; Izurieta HS; Korves C; Powell EI; Smith J; Balajee A; Holodniy M; Beenhouwer DO; Rodriguez-Barradas MC; Brown ST; Marconi VC
BMJ Open; 2022 Aug; 12(8):e063935. PubMed ID: 35922100
[TBL] [Abstract][Full Text] [Related]
17. Test negative case-control study of COVID-19 vaccine effectiveness for symptomatic SARS-CoV-2 infection among healthcare workers: Zambia, 2021-2022.
Mweso O; Simwanza J; Malambo W; Banda D; Fwoloshi S; Sinyange N; Yoo YM; Feldstein LR; Kapina M; Mulenga LB; Liwewe MM; Musonda K; Kapata N; Mwansa FD; Agolory S; Bobo P; Hines J; Chilengi R
BMJ Open; 2023 Dec; 13(12):e072144. PubMed ID: 38072491
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study.
Ioannou GN; Locke ER; O'Hare AM; Bohnert ASB; Boyko EJ; Hynes DM; Berry K
Ann Intern Med; 2022 Mar; 175(3):352-361. PubMed ID: 34928700
[TBL] [Abstract][Full Text] [Related]
19. Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance.
Britton A; Fleming-Dutra KE; Shang N; Smith ZR; Dorji T; Derado G; Accorsi EK; Ajani UA; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Mar; 327(11):1032-1041. PubMed ID: 35157002
[TBL] [Abstract][Full Text] [Related]
20. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
